Cipla Ltd is quoting at Rs 1286.4, down 1.05% on the day as on 13:19 IST on the NSE. The stock tumbled 14.73% in last one year as compared to a 3.15% rally in NIFTY and a 7.68% spurt in the Nifty ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the ...

The generic versions of semaglutide are expected to be at least 50% cheaper— ₹5,000 for a weekly dose—than Ozempic in India .

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement ...

With semaglutide patent ending, Indian pharma firms are set to launch lower-cost versions, prompting hospitals and clinics to expand obesity services ahead of a surge in demand.

Cipla Limited has announced the launch of Afrezza, the world's only available inhaled insulin for adults living with Diabetes Mellitus, offering a patient-centric and needle-free approach ...

Strategies Shaping Industry Growth. EINPresswire/ -- The Cell And Gene Therapy market is dominated by a mix of global biopharmaceutical leaders and specialized biotechnology innovators, with companies ...

Startups are also positioning themselves. New Delhi-based Enlighten Now Healthcare Pvt., which operates weight management platform Elevate Now, is adding corporate partnerships, tying up with large ...

With many diabetes mellitus (DM) patients struggling with the challenges of multiple daily insulin injections, there is a growing need for convenient and needle-free insulin delivery ...

Snehasis Bose, group chief strategy officer, Saatchi & Saatchi India, BBH India & Propagate India, talks to Christina Moniz ...